Agenus to Present at the 4th Annual Cancer Immunotherapy Conference

  Agenus to Present at the 4th Annual Cancer Immunotherapy Conference

4th Annual Cancer Immunotherapy Conference 2014

Business Wire

LEXINGTON, Mass. -- March 26, 2014

Agenus Inc. (Nasdaq: AGEN) today announced that Robert Stein, MD, PhD, Chief
Scientific Officer of Agenus, will be presenting on Agenus’ checkpoint
modulator portfolio and immuno-oncology strategy at the 4th Annual Cancer
Immunotherapy Conference at the New York Academy of Medicine in New York City.
On March 27, 2014, a presentation on Checkpoint Modulators is scheduled for
8:30 am Eastern Time and a corporate presentation is scheduled for 2:15 pm
Eastern Time.

Additionally, Dr. Stein will be participating on several panels, including:

9:30 am -10:15 am: Emerging Role of Combination Tumor Immunotherapies
11:45 pm -12:30 pm: Autologous Immunotherapies
4:00 pm - 4:30 pm: Immunotherapies for Solid Tumors

The corporate presentation will be webcast and accessible from the company’s
website at www.agenusbio.com/webcast/.

About Agenus

Agenus is a biopharmaceutical company developing a portfolio of
immuno-oncology candidates, including checkpoint modulators, heat shock
protein vaccines and adjuvants. The company’s proprietary discovery engine
Retrocyte Display^® is designed to rapidly generate high quality therapeutic
antibody drug candidates using a high-throughput approach incorporating IgG
format human antibody libraries expressed in mammalian B-lineage cells. A
portfolio of checkpoint modulator programs, including GITR, OX40 agonists and
CTLA-4, PD-1, LAG-3 and TIM-3 antagonists, is advancing in preclinical
development. The company’s heat shock protein vaccines for cancer and
infectious disease are in Phase 2 studies. Agenus’ QS-21 Stimulon^® adjuvant
platform is extensively partnered with GlaxoSmithKline and Janssen and
includes several candidates in Phase 3 trials. Among Agenus and its partners,
23 programs are in clinical development. For more information, please visit
www.agenusbio.com, or connect with the company on Facebook, LinkedIn, Twitter
and Google+.

Forward-Looking Statement

This press release contains forward-looking statements, including statements
regarding research and development activities of the Company and its
licensees. These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially. These
risks and uncertainties include, among others, the factors described under the
Risk Factors section of our Annual Report on Form 10-K filed with the
Securities and Exchange Commission for the period ended December 31, 2013.
Agenus cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These statements speak
only as of the date of this document, and Agenus undertakes no obligation to
update or revise the statements. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. Agenus’ business is
subject to substantial risks and uncertainties, including those identified
above. When evaluating Agenus’ business and securities, investors should give
careful consideration to these risks and uncertainties.

QS-21 Stimulon and Retrocyte Display are registered trademarks of Agenus and
its subsidiaries.

Contact:

Agenus Inc.
Media and Investor Contact:
Jonae R. Barnes, 617-818-2985
Vice President
Investor Relations
and Corporate Communications
jonae.barnes@agenusbio.com
 
Press spacebar to pause and continue. Press esc to stop.